These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1663 related articles for article (PubMed ID: 16288118)
1. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118 [TBL] [Abstract][Full Text] [Related]
2. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513 [TBL] [Abstract][Full Text] [Related]
3. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854 [TBL] [Abstract][Full Text] [Related]
4. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Vogel VG Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233 [TBL] [Abstract][Full Text] [Related]
5. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. Swerdlow AJ; Jones ME; J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574 [TBL] [Abstract][Full Text] [Related]
6. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304 [TBL] [Abstract][Full Text] [Related]
7. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Chalas E; Costantino JP; Wickerham DL; Wolmark N; Lewis GC; Bergman C; Runowicz CD Am J Obstet Gynecol; 2005 Apr; 192(4):1230-7; discussion 1237-9. PubMed ID: 15846210 [TBL] [Abstract][Full Text] [Related]
8. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR; J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757 [TBL] [Abstract][Full Text] [Related]
9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
10. Chemoprevention: drug pricing and mortality: the case of tamoxifen. Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680 [TBL] [Abstract][Full Text] [Related]
11. The cost effectiveness of tamoxifen in the prevention of breast cancer. Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851 [TBL] [Abstract][Full Text] [Related]
12. The nature of tamoxifen action in the control of female breast cancer. Kodama M; Kodama T In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224 [TBL] [Abstract][Full Text] [Related]
13. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248 [TBL] [Abstract][Full Text] [Related]
14. Tamoxifen: an enduring star. Veronesi U; Maisonneuve P; Decensi A J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297 [No Abstract] [Full Text] [Related]
15. Stroke risk and tamoxifen therapy for breast cancer. Geiger AM; Fischberg GM; Chen W; Bernstein L J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603 [TBL] [Abstract][Full Text] [Related]
16. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
17. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Vogel VG; Costantino JP; Wickerham DL; Cronin WM Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Rutqvist LE; Johansson H; Acta Oncol; 2007; 46(2):133-45. PubMed ID: 17453361 [TBL] [Abstract][Full Text] [Related]
20. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L; Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]